A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

Condition:   Non-valvular Atrial Fibrillation (NVAF) Intervention:   Drug: Rivaroxaban (Xarelto,Bay 59-7939) Sponsors:   Bayer;   Janssen Research & Development, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials